The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
BACKGROUND
When adjusted for inflation, the federal investment in human immunodeficiency virus (HIV) prevention in the United States has been trending downward for several years. However, for fiscal year 2007, President Bush has proposed to Congress a $93 million increase in HIV prevention efforts focused on HIV counseling and rapid testing in high-risk communities.


OBJECTIVE
Here, we estimate the coverage level of an investment of $93 million for rapid testing and counseling services, estimate the number of HIV infections that might be expected to be prevented by this initiative, and calculate the cost-per-infection-prevented.


METHODS
Standard methods of scenario and cost-effectiveness analysis were employed, and a 1-year time horizon was used. Calculations were done assuming both a societal perspective and a payor perspective.


RESULTS
Assuming full societal perspective costs, about 1.4 million clients could be reached, but if the payor's perspective is used (and clients are assumed to absorb the costs of their time spent and transportation), then coverage could expand to 2.9 million clients. Depending on the perspective used, it is estimated that between 13,014 and 26,984 persons living with HIV could newly learn their serostatus, and that between 1,223 and 2,537 HIV infections could be prevented as a function of the initiative. Under both societal and payor perspectives, the gross cost per infection averted is less than the medical care costs for one case of HIV disease.


CONCLUSIONS
We conclude that the president's proposed $93 million initiative for HIV counseling and rapid testing in the United States would have favorable public health benefits and be cost saving to society (even if it does not address all unmet HIV prevention needs in the United States). However, future research should seek to determine whether rapid counseling and testing are the optimal use of a new $93 million investment in HIV prevention.
Holtgrave
David R
DR
Department of Health, Behavior & Society at the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA. dholtgrave@jhsph.edu
D015492:AIDS Serodiagnosis / Q000191:economics; D003362:Cost-Benefit Analysis; D003376:Counseling / Q000191:economics; D035082:Federal Government; D005380:Financing, Government; D015658:HIV Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D006291:Health Policy; D006801:Humans; D010353:Patient Education as Topic / Q000191:economics; D011314:Preventive Health Services / Q000191:economics*; D011322:Primary Prevention / Q000191:economics / Q000379:methods; D015397:Program Evaluation; D014481:United States / Q000453:epidemiology